GR3031459T3 - Wound treatment employing biologically active peptides - Google Patents

Wound treatment employing biologically active peptides

Info

Publication number
GR3031459T3
GR3031459T3 GR990402550T GR990402550T GR3031459T3 GR 3031459 T3 GR3031459 T3 GR 3031459T3 GR 990402550 T GR990402550 T GR 990402550T GR 990402550 T GR990402550 T GR 990402550T GR 3031459 T3 GR3031459 T3 GR 3031459T3
Authority
GR
Greece
Prior art keywords
biologically active
wound treatment
active peptides
treatment employing
wound
Prior art date
Application number
GR990402550T
Other languages
English (en)
Inventor
Barry Berkowitz
Leonard S Jacob
Michael Zasloff
Original Assignee
Magainin Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Sciences Inc filed Critical Magainin Sciences Inc
Publication of GR3031459T3 publication Critical patent/GR3031459T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
GR990402550T 1989-12-18 1999-10-07 Wound treatment employing biologically active peptides GR3031459T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/451,777 US5045531A (en) 1989-12-18 1989-12-18 Wound treatment employing biologically active ion channel forming peptides and proteins
PCT/US1990/007440 WO1991008758A1 (en) 1989-12-18 1990-12-12 Wound treatment employing biologically active peptides

Publications (1)

Publication Number Publication Date
GR3031459T3 true GR3031459T3 (en) 2000-01-31

Family

ID=23793638

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402550T GR3031459T3 (en) 1989-12-18 1999-10-07 Wound treatment employing biologically active peptides

Country Status (10)

Country Link
US (2) US5045531A (el)
EP (1) EP0505497B1 (el)
JP (1) JPH05504566A (el)
AT (1) ATE181835T1 (el)
CA (1) CA2032059C (el)
DE (1) DE69033200T2 (el)
DK (1) DK0505497T3 (el)
ES (1) ES2136599T3 (el)
GR (1) GR3031459T3 (el)
WO (1) WO1991008758A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000194A1 (en) * 1987-07-06 1989-01-12 Louisiana State University Agricultural And Mechan Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
CA1327311C (en) * 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
US5912231A (en) * 1989-07-07 1999-06-15 Scripps Clinic And Research Foundation Substitution analogues of magainin peptides
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
NZ237202A (en) * 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
EP0671930A4 (en) * 1991-07-25 1996-02-07 Magainin Pharma PROPHYLAXIS AND TREATMENT OF HEALTH DAMAGE TO DENTAL HYGIENE BY BIOLOGICALLY ACTIVE PEPTIDES.
WO1994001451A2 (en) * 1992-07-13 1994-01-20 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5656456A (en) * 1992-07-13 1997-08-12 Bionebraska, Inc. Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
AU6251594A (en) * 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Treatment of cancerous growths with biologically active peptides and protease inhibitors
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5968904A (en) * 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation
US5856178A (en) * 1993-08-30 1999-01-05 Utah State University DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same
WO1995011670A1 (en) * 1993-10-25 1995-05-04 The Liposome Company, Inc. Liposomal defensins
WO1995013085A1 (en) 1993-11-08 1995-05-18 Demeter Biotechnologies Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
FR2735983B1 (fr) * 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
JP3860838B2 (ja) 1995-08-23 2006-12-20 ユニバーシティー オブ ブリティッシュ コロンビア 抗微生物性陽イオン性ペプチドおよびそのスクリーニング方法
US6077826A (en) * 1996-01-25 2000-06-20 Kansas State University Research Foundation Synthetic macromolecular channel assembly for transport of chloride ions through epithelium useful in treating cystic fibrosis
WO1997039764A1 (fr) * 1996-04-23 1997-10-30 Toray Industries, Inc. Agent anti-pylori
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
WO2005094423A2 (en) * 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
WO2009070564A2 (en) * 2007-11-27 2009-06-04 Macrochem Corporation Compositions and methods for prevention of infection in transcutaneous osseointegrated implants
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507230A (en) * 1982-05-12 1985-03-26 Research Corporation Peptide synthesis reagents and method of use
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4810777A (en) * 1987-03-04 1989-03-07 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial compounds
EP0346429B1 (en) * 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US4962277A (en) * 1988-12-09 1990-10-09 Scripps Clinic And Research Foundation Deletion analogues of magainin peptides
US5073542A (en) * 1989-06-07 1991-12-17 Magainin Sciences Inc. CPF peptide compositions and their use in inhibiting growth of target cells or a virus

Also Published As

Publication number Publication date
JPH05504566A (ja) 1993-07-15
US5045531A (en) 1991-09-03
EP0505497A4 (en) 1993-09-08
CA2032059A1 (en) 1991-06-19
CA2032059C (en) 2003-02-25
WO1991008758A1 (en) 1991-06-27
DE69033200T2 (de) 2000-02-24
EP0505497B1 (en) 1999-07-07
USRE35492E (en) 1997-04-08
ATE181835T1 (de) 1999-07-15
ES2136599T3 (es) 1999-12-01
DE69033200D1 (de) 1999-08-12
DK0505497T3 (da) 1999-11-22
EP0505497A1 (en) 1992-09-30

Similar Documents

Publication Publication Date Title
GR3031459T3 (en) Wound treatment employing biologically active peptides
GEP20002146B (en) Therapeutic Peptide Derivatives
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
GR3023874T3 (en) Igf-1 to improve the neural condition.
GEP20063773B (en) Steroid Sulphatase Inhibitors
IL76932A0 (en) Pharmaceutical compositions containing dihydrocodeine and ibuprofen
SG1893G (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
EP0906119A4 (en) TREATMENT PROCEDURE
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
HU9502573D0 (en) Recombinant adenoviruses and use thereof in gene therapy
DE69429365D1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
AU5323396A (en) Methods of treating inflammation and compositions therefor
AU5743194A (en) Treatment of dermatological malignancies with biologically active peptides
ES2024729A6 (es) Metodo de ensayar muestras desconocidas de fluido biologico para detectar peptidos formadores de canales de iones.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
WO1992018536A3 (en) Method for detecting an localizing tissues having neurokinine 1 receptors
NZ332688A (en) Stimulation of host defence mechanisms against tumors using interferon
AU9034291A (en) Derivates of the human parathormone fragment (1-37) in the amide or ethylamide form as active substance
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
AU3039789A (en) Active substance for treating changes in the skin and mucous membranes
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
UA10276A (uk) Спосіб лікування розсіяного склерозу